Soligenix (SNGX)
Develops rare-disease therapeutics and heat-stable biodefense vaccine candidates.
Something off on this page? Send us feedback.
Develops rare-disease therapeutics and heat-stable biodefense vaccine candidates through Specialized BioTherapeutics and Public Health Solutions. With no commercial product sales, its model relies on clinical and regulatory progress, partnership activity and government-backed public-health funding.
Operates through Specialized BioTherapeutics, which develops orphan-disease candidates, and Public Health Solutions, which pursues heat-stable biodefense vaccines and infectious-disease therapeutics. Its active clinical focus is dusquetide for Behçet's disease; a visible-light-activated synthetic-hypericin gel remains in development for psoriasis. An oral-mucositis program requires a partner and another late-stage trial.
Uses orphan-disease development expertise, in-licensed technology and partners or out-licenses to take programs forward, directly managing clinical studies while outsourcing parts of development and manufacturing. Work spans the United States, Europe and the United Kingdom, including public-health efforts tied to U.S. agencies and university research. No products are approved or sold.
ThermoVax provides a heat-stabilization platform for subunit vaccines, including ricin and filovirus candidates. RiVax's regulatory path depends on the FDA Animal Rule and validated immune correlates, and Public Health Solutions development is contingent on continued government grants, contracts or other support.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $9.8M · Total debt $302.6K · Total assets $10.5M · Shareholders' equity $6.6M
- Revenue
- $0
- Operating income
- −$2.1M
- Net income
- −$2.0M
No dividends on record.
| Institutions | 4.30% | 936.5K shares | |
|---|---|---|---|
| 15 holders · as of Jun 30, 2026 | |||
| Insiders | 0.07% | 15.5K shares | |
| 1 holder · as of Oct 3, 2025 | |||
| Strategic holders | 0.04% | 9.7K shares | |
| 1 holder · as of Jul 9, 2018 | |||
| Other | 95.59% | 20.80M shares | |
| remainder | |||
21.77M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (21.77M in the company's Sep 23, 2026 report, 14.82M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
MJL Manager LLCInstitution | 4.11% | 893,588 | filed Jun 25, 2026 |
Citadel Advisors LLCInstitution | 0.96% | 209,507 | as of Jun 30, 2026 |
Jane Street Group, LLCInstitution | 0.95% | 207,492 | as of Jun 30, 2026 |
XTX Topco LtdInstitution | 0.72% | 157,119 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.55% | 120,267 | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Oct 2, 2025 | Christopher J. Schaber | director, officer: CHAIRMAN, CEO AND PRESIDENT | +15,132 | $1.32 |
- Amgen
Dominant approved therapy in Behçet's oral ulcers and psoriasis.
- Arcutis Biotherapeutics
Approved topical psoriasis therapy with a broad dermatology sales force.
- Vaxart
Room-temperature vaccine platform competing on cold-chain avoidance.
- Innate Pharma (ADR)
Named emerging rival in innate-immune therapeutic research.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Soligenix | $0.3831 | −0.49% | $5.7M | — | — | — | — |
| Amgen | $408.65 | −0.39% | $221.41B | 25.5 | 17.4 | 5.8 | +9.7% |
| Arcutis Biotherapeutics | $26.19 | −5.74% | $3.47B | 133.2 | 33.2 | 7.5 | +59.3% |
| Vaxart | $0.4740 | −1.27% | $117.3M | 3.2 | — | 0.5 | −31.6% |
| Innate Pharma (ADR) | $1.78 | −1.39% | $169.0M | — | — | 136.6 | +12.9% |
| Median | 25.5 | 25.3 | 6.6 | +11.3% |